Cellceutix Corp. (CTIX.OB) Wraps Up Toxicology Studies as Human Trials Near for Kevetrin
Cellceutix Corp. announced today that they have received nearly all the data regarding the toxicology studies for Kevetrin™, the Company’s flagship compound for the treatment of multi-drug-resistant cancers. The remaining data is expected within two or three weeks. This data is the final information required for the Investigational New Drug Application (IND) to be prepared and submitted to the U.S. Food and Drug Administration. In preparation for the filing, Cellceutix has engaged additional consultation to bring Kevetrin to human trials. George Evans, CEO of Cellceutix, commented, "We are continuing to hit our targets at or ahead of schedule with Kevetrin.…